Go Pro
→ The Starlink of Energy (From Monument Traders Alliance) (Ad)tc pixel
OTCMKTS:HYPMY

Hypermarcas Q2 2025 Earnings Report

Hypermarcas logo
$4.13 -0.03 (-0.78%)
As of 03:36 PM Eastern
ProfileEarnings HistoryForecast

Hypermarcas EPS Results

Actual EPS
$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hypermarcas Announcement Details

Quarter
Q2 2025
Date
8/6/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Conference Call Resources

Hypermarcas Earnings Headlines

Hypera SA ADR (HYPMY)
May 24, 2026  |  investing.comhttps://www.investing.com/equities/hypermarcas-sa-financial-summary
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
October 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4834950-hypera-s-a-hypmy-q3-2025-earnings-call-transcript
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.tc pixel
August 6 at 1:00 AM  |  Brownstone Research (Ad)
Brazil's Hypera announces new majority stakeholder group
July 7, 2025  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/brazils-hypera-announces-new-majority-stakeholder-group-2025-07-07/
Hypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/HYPMY
Hypera S.A. credit rating downgraded due to increased leverage
April 9, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/hypera-sa-credit-rating-downgraded-due-to-increased-leverage-93CH-3977909
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands.

Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.

View Hypermarcas Profile
Earnings Tools